Tamsulosin Hydrochloride Capsule
Product Images NDC 72162-2217

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 72162-2217). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721622217)

Label for Tamsulosin Hydrochloride Capsules, USP 0.4 mg, in a package containing 500 capsules. The label includes directions for storage at controlled room temperature and safety warnings. It is labeled by Bryant Ranch Prepack and manufactured by Aurobindo Pharma Limited. The NDC is 72162-2217.*

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

A line graph showing mean plasma concentrations of Tamsulosin Hydrochloride over 36 hours after a single 0.4 mg oral dose under fasted and fed conditions. The vertical axis is plasma concentration (ng/mL) and the horizontal axis is time (hours). Two lines compare concentration changes under fasted (dashed line) and fed (solid line) states in eight subjects.*

FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

A line graph titled 'Figure 2A Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1' showing mean change in symptom score on the y-axis against duration of treatment in weeks on the x-axis. Three treatments are compared: 0.8 mg, 0.4 mg, and placebo. The graph shows greater symptom score improvement with the 0.8 mg and 0.4 mg treatments compared to placebo over 13 weeks.*

FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

Line graph showing mean change from baseline in total AUA symptom score over 13 weeks of treatment. The x-axis represents treatment duration in weeks, and the y-axis shows mean change in symptom score. Three treatment groups are plotted: 0.8 mg dose, 0.4 mg dose, and placebo. Both active doses show greater symptom score reduction over time compared to placebo.*

FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

A line graph titled 'Figure 3A Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1' depicting mean change in urine flow rate over treatment duration in weeks. It compares three groups: 0.8 mg treatment (circles), 0.4 mg treatment (triangles), and placebo (squares). The y-axis shows mean change in mL/sec, ranging from 0 to 3.0, and the x-axis shows weeks from baseline (B) to 13 including last observed case (LOCF).*

FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

Line chart titled 'Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2' showing mean change in urine flow rate over treatment duration in weeks. The chart compares three treatments: 0.8 mg, 0.4 mg, and placebo, using different markers for each. The x-axis represents treatment duration in weeks, and the y-axis shows mean change in flow rate (mL/sec).*

FDA Label Image

Chemical Structure (Tamsulosin Str)

Chemical structure diagram of Tamsulosin Hydrochloride showing its molecular components, including aromatic rings, functional groups, and the HCl salt form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.